Singapore-based clinical stage biotech firm Lion TCR has raised $20 million in a Series A funding round from new investors Yashang Capital and US-based early stage investor Westlake Ventures Capital apart from undisclosed existing investors.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
